Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial-Reference-Cited by-同舟云学术

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

Published:2002-06 Issue:9324 Volume:359 Page:2131-2139
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Publisher

Elsevier BV

Subject

General Medicine

Reference28 articles.

1. Endocrine treatment of breast cancer in women;Santen;Endocr Rev,1990

2. Recent advances in endocrine therapy of breast cancer;Howell;BMJ,1997

3. Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer;Lancet,1983

4. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer;J Natl Cancer Inst,1996

5. Tamoxifen for early breast cancer: an overview of the randomised trials;Lancet,1998

Cited by 1434 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The anti-aromatase and anti-estrogenic activity of plant products in the treatment of estrogen receptor-positive breast cancer;The Journal of Steroid Biochemistry and Molecular Biology;2024-10

2. Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole;European Journal of Cancer;2024-09

3. Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care – The PreFace Study;Senologie - Zeitschrift für Mammadiagnostik und -therapie;2024-05-23

4. Progressive relaxation training in patients with breast cancer receiving aromatase inhibitor therapy-randomized controlled trial;PLOS ONE;2024-04-18

5. Real-world data of cardio-oncologic interventions for cardiovascular adverse events with oral oncolytics;Cardio-Oncology;2024-04-09